Indiana University Research and Technology Corp. Patent applications |
Patent application number | Title | Published |
20150197522 | INAUHZIN ANALOGUES THAT INDUCE P53, INHIBIT CELL GROWTH, AND HAVE ANTITUMOR ACTIVITY - Inauhzin (INZ) was identified as a novel p53 activator, which selectively and efficiently suppressing tumor growth without displaying genotoxicity and with little toxicity to normal cells. A panel of INZ analogs were synthesized and evaluated their ability to induce cellular p53 and to inhibit cell growth in cell-based assays. As described, this leads to the discovery of INZ analog 37, a molecule that exhibits much better potency than INZ in both of p53 activation and cell growth inhibition in several human cancer cell lines including H460 and HCT116 | 07-16-2015 |
20140221607 | MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY - The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression. | 08-07-2014 |
20140193473 | MATERIALS AND METHODS FOR CONTROLLING VASCULOGENESIS FROM ENDOTHELIAL COLONY FORMING CELLS - Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior. | 07-10-2014 |
20140121214 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS - Germline mutations in the NF1 tumor suppressor gene cause Von Recklinghausen's neurofibromatosis type 1 (NF1), a common genetic disorder of the nervous system characterized by plexiform neurofibroma development. Using adoptive transfer of hematopoietic cells, we establish that NF1 heterozygosity of bone marrow derived cells in the tumor microenvironment is sufficient to allow neurofibroma progression in the context of Schwann cell nullizygosity. Further, genetic or pharmacologic attenuation of the c-kit signaling pathway in hematopoietic cells greatly diminishes neurofibroma initiation and progression. These studies identify haploinsufficient hematopoietic cells and the c-kit receptor as therapeutic targets for preventing plexiform neurofibromas and implicate mast cells as critical mediators of tumor initiation. Administering therapeutically effective doses of a tyrosine kinase inhibitor such as the compound imatinib mesylate to a patient in need thereof to treat tumors in a human patient afflicted with plexiform neurofibroma. | 05-01-2014 |
20140065706 | MATERIALS AND METHODS FOR MOBILIZING CELLS INCLUDING CD34+, HEMATOPOIETIC COLONY FORMING, AND ENDOTHELIAL COLONY FORMING CELLS - Disclosed herein are materials and methods such as the use of none steroidal anti-inflammatory drugs to increase the number of CD34+ cell in human patients. The level of ECFC measured in volunteers before and after treatment with meloxicam. Only 4/7 volunteers had detectable levels of ECFC in a 40 mL sample of peripheral of blood (PB) before treatment, while 7/7 had detectable levels of ECFC in a similar sample collected post-meloxicam treatment. Administering a course of treatment with NSAID also increased the number of endothelial colony forming cells (ECFC) in the volunteers PB and it reduced culture time to first ECFC detection. These data demonstrate that NSAID administration mobilizes both hematopoietic and endothelial progenitors to PB. This provides a safe and effective strategy that can be added to existing mobilization regimens and is especially useful when combined with a course of treatment that includes the use of G-CSF. | 03-06-2014 |
20140017786 | SMALL MOLECULE INHIBITORS OF REPLICATION PROTEIN A THAT ALSO ACT SYNERGISTICALLY WITH CISPLATIN - Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC | 01-16-2014 |
20140017339 | MATERIALS AND METHODS FOR TREATING RADIATION POISONING - Disclosed herein are materials and methods for treating patients that have been exposed to pathological levels on ionizing radiation. These materials and methods include administering to a patient in thereof at least one dose of a compound such as prostaglandin (PGE | 01-16-2014 |
20120172295 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS - Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein. | 07-05-2012 |
20120038885 | DEVICES AND METHODS FOR POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHY AND ADAPTIVE OPTICS - The present disclosure includes disclosure of devices, and methods to resolve microscopic structures. In at least one exemplary embodiment, a visualization apparatus comprises a source arm having a light source operable to emit a light beam, wherein the light beam defines a beam pathway, a reference arm comprising a reflecting surface positioned within the beam pathway, a sample arm comprising a wavefront sensor, an adaptive optics wavefront corrector, and a target, each of which are positioned within the beam pathway, wherein the adaptive optics wavefront sensor is operable to compensate for at least one aberration in the light beam, a detector arm comprising a beam detector positioned within the beam pathway, wherein the beam detector is operable to detect the reflected light beam from the reference arm and the target, and wherein the visualization apparatus is operable to minimize at least one aberration of the target. | 02-16-2012 |